PRESS RELEASE

Tiancheng (Germany) Pharmaceutical Holdings AG crosses 75% acceptance threshold in Biotest tender offer

Munich, 14 June 2017 - Tiancheng (Germany) Pharmaceutical Holdings AG, a company indirectly controlled by Creat Group Corporation, ("Bidder"), announced today that it has crossed the required minimum acceptance threshold of at least 75% of all Biotest ordinary shares for its voluntary takeover offer for all outstanding shares in Biotest AG ("Biotest"). As of 14 June 2017 at 12:30 hrs (Frankfurt am Main local time), the takeover offer has been accepted for 15,244,289 Biotest ordinary shares, which corresponds to 77.05% of the voting share capital and 38.52% of the total share capital of Biotest and 86,673 Biotest preference shares, which corresponds to 0.22% of the total share capital of Biotest.

Biotest ordinary and preference shareholders who have not yet accepted the offer, which has been strongly recommended by the Biotest Management and Supervisory Board, can still tender their shares to the Bidder, at unchanged terms, until the end of the initial acceptance period, on 15 June 2017 at 24:00 hrs (Frankfurt am Main local time)/18:00 hrs (New York local time) and during the mandatory additional acceptance period, which is expected to commence on 22 June 2017 and to end on 5 July 2017. As outlined in the offer document, the Bidder offers Biotest shareholders EUR28.50 per Biotest ordinary share and EUR19.00 per Biotest preference share in cash.

The official offer document as well as a presentation summarizing the key points of the offer are available at http://www.tiancheng-germany-pharmaceutical-angebot.de.

Mr Wu Xu, CEO of Creat, says: "We are delighted that a large majority of Biotest ordinary shareholders has accepted our offer. Especially against the backdrop of recent operational challenges at Biotest and the company's difficult multi-year transition period, our offer will deliver immediate value for stakeholders and long-term value for Biotest as a company. We invite shareholders of both share classes who have not yet tendered to accept the offer in line with the Biotest Management and Supervisory Boards' recommendation."

The completion of the takeover offer is still subject to foreign investment control and merger control approvals. Merger control approval in the United States has already been granted.

About Creat Group Corporation

Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, and natural resources. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai. Through its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory, Creat is a significant investor in the global plasma market.

Important Notice

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Biotest. The definite terms and conditions of the takeover offer, as well as further provisions concerning the takeover offer, have been published in the offer document following approval by the German Federal Financial Supervisory Authority. Investors and holders of shares in Biotest are strongly advised to read the offer document and all other relevant documents regarding the takeover offer, since they contain important information.
The takeover offer has been issued exclusively under the laws of the Federal Republic of Germany and certain applicable provisions of U.S. securities law. Any contract that is concluded on the basis of the takeover offer is exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.

Media Contact

Knut Engelmann
CNC - Communications & Network Consulting AG
T +49 69 506 037 570